Pfizer has entered into a marketing agreement with Claris Lifesciences, an Indian firm specialising in injectables. As per the agreement, Pfizer gains marketing rights for Claris’s 15 injectable products spread across various therapeutic areas such as pain and anti-infectives. Pfizer will market these products under its brand name.
Subscribe to our email newsletter
The deal extends reach of Claris’s products in Europe, North America and Australia.
Pfizer will undertake the commercialisation of the products that have gone off-patent in the western markets. The move will expand Pfizer’s generic drugs portfolio.
Claris manufactures and markets injectables with emphasis on New Drug Delivery Systems for treatment of critical illnesses and diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.